Neuropharmacologic targets and agents in fibromyalgia.
Chronic widespread pain is a primary feature of fibromyalgia and is a symptom that is poorly managed in many patients. In addition, patients often experience fatigue, sleep disturbances, and anxiety. Its etiology is largely unknown. The successful clinical management of this syndrome relies on a multidisciplinary approach, employing pharmacologic and nonpharmacologic treatments. Clinical evidence on the symptoms and characteristics of fibromyalgia suggests a central mechanism behind the pathogenesis of this syndrome. It is likely that drugs with central actions will prove to be effective against a number of symptoms. This article aims to outline some of the potential spinal pharmacologic targets that may be used to treat this condition.
Suzuki
Rie
R
Department of Pharmacology, University College London, Gower Street, London, WC1E 6BT, United Kingdom. ucklrsu@ucl.ac.uk
Dickenson
Anthony H
AH
D002491:Central Nervous System Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005356:Fibromyalgia / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D010348:Patient Care Team; D017981:Receptors, Neurotransmitter / Q000187:drug effects / Q000502:physiology; D013116:Spinal Cord / Q000187:drug effects* / Q000503:physiopathology; D009435:Synaptic Transmission / Q000187:drug effects / Q000502:physiology; D016896:Treatment Outcome
D002491:Central Nervous System Agents; D017981:Receptors, Neurotransmitter